(Information sent by the signatory company)
Five centers acquired in the Czech Republic
LUCCA, Italy, Dec. 6, 2022 /PRNewswire/ -- Kedrion, an Italy-based global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutics for use in the treatment of serious diseases and conditions, announced the acquisition of the Czech companies UNICAplasma s.r.o. and UNICAplasma Morava s.r.o., which operate five plasma collection centers in the Czech Republic.
The centers, which have an annual collection capacity of approximately 70,000 litres, are managed throughout the territory of the Czech Republic under two different brands: UNICAplasma in Prague and Mojeplazma in Kladno, Ostrava, Frýdek-Místek and Český Těšín.
"We believe this acquisition will greatly enhance the value of our company," said Paolo Marcucci, Kedrion's Chairman and CEO, enabling us to become a player in plasma collection in Europe. Through this operation, we will be able to secure an increasing amount of high-quality plasma for our production plants, this unique and special raw material for the production of plasma-derived products crucial to prevent and treat rare and debilitating conditions."
“We are very proud to add these new companies to the Kedrion group, added Paolo Marcucci, and we welcome all new employees to our corporate family. We also give a special welcome to donors – your contribution is vital to help provide life-enhancing and life-saving therapies to the growing number of patients we serve around the world.”
The centers will continue to be managed by Milan Maly, one of the pioneers of the sector in the Czech Republic (the Prague center started operations in 2008). Maly is also the founder and president of the Czech Plasma Association and president of the European Plasma Alliance (EPA), the European association of plasma collectors.
Kedrion is an Italian-founded biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutics worldwide for use in treating patients with hemophilia, primary immunodeficiencies, and other serious diseases.
In 2022, Kedrion has joined forces with BPL (Bio Products Laboratory). Headquartered in the UK, BPL operates a dedicated portfolio of successful plasma-derived products to treat rare diseases. The company is the world's fifth largest player in the field of plasma-derived products.
Logo - https://mma.prnewswire.com/media/1736227...
View original content: https://www.prnewswire.com/news-releases/kedrion-refuerza-su-red-de-centros-de-recogida-de-plasma-301695927.html